All In Biotech

Free tool

FAERS Monitor: Sotyktu

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214958 or its brand name (Sotyktu, Deucravacitinib). Reports on generic versions are filed under their own applications.

Reports

2,976

Serious

619

21% of reports

Hospitalization

163

Death reported

46

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective286
  • acne255
  • pruritus244
  • rash206
  • psoriasis190
  • erythema171
  • off label use120
  • skin burning sensation88
  • product dose omission issue83
  • adverse event82
  • headache82
  • pain79
  • mouth ulceration76
  • folliculitis67
  • diarrhoea62

Reports by year received

View as table
YearReports
20201
20211
2022140
20231,053
2024850
2025579
2026352

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,183 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
folliculitisSignal6745.435.82,851
mouth ulcerationSignal7625.620.51,766
acneSignal25523.821.25,560
psoriasisSignal19010.39.01,593
skin burning sensationSignal888.77.1593
adverse eventSignal826.35.1361
erythemaSignal1715.95.1694
pruritusSignal2444.54.0670
rashSignal2063.32.9343
product dose omission issue832.01.641
drug ineffective2861.51.456
off label use1201.00.80
headache820.90.70
pain790.90.71
diarrhoea620.70.59

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.